Human Antibodies from Transgenic Mice

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 115-150

  Lonberg, Nils ^a  

^a Medarex   (United States)

Author keywords

Antibody sources and human antibodies from transgenic mice; Human therapeutic applications of transgenic mouse derived MAbs; Immunoglobulin gene role in B cell development

Indexed keywords

EID: 84891011879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch5     Document Type: Chapter

References (207)

1. Aikawa, T., J. Gunn, S.M. Spong, S.J. Klaus, and M. Korc. 2006. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. CancerTher. 5(5):1108-1116.
2. Akiyoshi, D.E., C.M. Rich, S. O'Sullivan-Murphy, L. Richard, J. Dilo, A. Donohue-Rolfe, A.S. Sheoran, S. Chapman-Bonofiglio, and S. Tzipori. 2005. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infect. Immun. 73(7):4054-4061.
3. Alt, F.W., T.K. Blackwell, and G.D. Yancopoulos. 1985. Immunoglobulin genes in transgenic mice. Trends Genet. 1,231-236.
4. Attia, P., G.Q. Phan, A.V. Maker, M.R. Robinson, M.M. Quezado, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, N.P. Restifo, L.R. Haworth, C. Levy, S.A. Mavroukakis, G. Nichol, M.J. Yellin, and S.A. Rosenberg. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25):6043-6053.
5. Babcock, G.J., T.J. Broering, H.J. Hernandez, R.B. Mandell, K. Donahue, N. Boatright, A.M. Stack, I. Lowy, R. Graziano, D. Molrine, D.M. Ambrosino, and W.D. Thomas, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74(11):6339-6347.
6. Baert, F., M. Noman, S. Vermeire, G. Van Assche, A. Carbonez, and P. Rutgeerts. 2003. Influence of immunogeni-city on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7):601-608.
7. Ball, W.J., Jr., R. Kasturi, P. Dey, M.Tabet, S. O'Donnell, D. Hudson, and D. Fishwild. 1999. Isolation and characterization of human monoclonal antibodies to digoxin. J. Immunol. 163(4):2291-2298.
8. Bankovich, A.J., S. Raunser, Z.S. Juo, T. Walz, M.M. Davis, and K.C. Garcia. 2007. Structural insight into pre-B cell receptor function. Science 316(5822):291-294.
9. Barbas, C.F. III, and D.R. Burton. 1996. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol. 14(7):230-234.
10. Barreto, V., B. Reina-San-Martin, A.R. Ramiro, K.M. McBride, and M.C. Nussenzweig. 2003. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol. Cell 12(2):501-508.
11. Baslund, B., N. Tvede, B. Danneskiold-Samsoe, P. Larsson, G. Panayi, J. Petersen, L.J. Petersen, F. J. Beurskens, J. Schuurman, J.G. van de Winkel, P.W. Parren, J.A. Gracie, S. Jongbloed, F.Y. Liew, and I.B. McInnes. 2005. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52(9):2686-2692.
12. Bastholt, L., L. Specht, K. Jensen, E. Brun, A. Loft, J. Petersen, H. Kastberg, and J.G. Eriksen. 2007. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 85(1):24-28.
13. Beck, K.E., J.A. Blansfield, K.Q. Tran, A.L. Feldman, M.S. Hughes, R.E. Royal, U.S. Kammula, S.L. Topalian, R.M. Sherry, D. Kleiner, M. Quezado, I. Lowy, M. Yellin, S.A. Rosenberg, and J.C. Yang. 2006. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24(15):2283-2289.
14. Bekker, P.J., D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, and A.M. DePaoli. 2004. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19(7):1059-1066.
15. Bender, N.K., C.E. Heilig, B. Droll, J. Wohlgemuth, F.P. Armbruster, and B. Heilig. 2007. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 27(3):269-274.
16. Benedict, C.L., S. Gilfillan, T.H. Thai, and J.F. Kearney. 2000. Terminaldeoxynucleotidyltransferaseandrepertoire development. Immunol. Rev. 175:150-157.
17. Blansfield, J.A., K.E. Beck, K. Tran, J.C. Yang, M.S. Hughes, U.S. Kammula, R.E. Royal, S.L. Topalian, L.R. Haworth, C. Levy, S.A. Rosenberg, and R.M. Sherry. 2005. Cytotoxic T-lymphocyte-associated anti-gen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. (1997) 28(6):593-598.
18. Bleeker, W.K., J.J. Lammerts van Bueren, H.H. van Ojik, A.F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M.A. van Dijk, J.G. van de Winkel, and P.W. Parren. 2004. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 173(7):4699-4707.
19. Bleeker, W.K., M.E. Munk, W.J. Mackus, J.H. van den Brakel, M. Pluyter, M.J. Glennie, J.G. van de Winkel, and P.W. Parren. 2008. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140(3):303-312.
20. Body, J.J., T. Facon, R.E. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M.C. Peterson, and P.J. Bekker. 2006. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12(4):1221-1228.
21. Boll, B., H. Hansen, F. Heuck, K. Reiners, P. Borchmann, A. Rothe, A. Engert, and E. Pogge von Strandmann. 2005. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezo-mib-induced apoptosis. Blood 106(5):1839-1842.
22. Borchmann, P., R. Schnell, and A. Engert. 2005. Immunotherapy of Hodgkin's lymphoma. Eur. J. Haematol. Suppl. 75(66):159-165.
23. Borchmann, P., R. Schnell, H. Schulz, and A. Engert. 2004. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma. Curr. Opin. Investig. Drugs 5(12):1262-1267.
24. Borchmann, P., J.F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.F. Zhang, T. Davis, T. Keler, V. Diehl, R.F. Graziano, and A. Engert. 2003. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102(10):3737-3742.
25. Brinster, R.L., H.Y. Chen, M. Trumbauer, A.W. Senear, R. Warren, and R.D. Palmiter. 1981. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell 27(1, Pt 2):223-231.
26. Brinster, R.L., K.A. Ritchie, R.E. Hammer, R.L. O'Brien, B. Arp, and U. Storb. 1983. Expression of a microinjected immunoglobulin gene in the spleen of transgenic mice. Nature 306(5941):332-336.
27. Bruggemann, M., H.M. Caskey, C. Teale, H. Waldmann, G.T. Williams, M.A. Surani, and M.S. Neuberger. 1989. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc. Natl. Acad. Sci. USA 86(17):6709-6713.
28. Bucchini, D., C.A. Reynaud, M.A. Ripoche, H. Grimal, J. Jami, and J.C. Weill. 1987. Rearrangement of a chicken immunoglobulin gene occurs in the lymphoid lineage of transgenic mice. Nature 326(6111):409-411.
29. Burgess, T., A. Coxon, S. Meyer, J. Sun, K. Rex, T. Tsuruda, Q. Chen, S.Y. Ho, L. Li, S. Kaufman, K. McDorman, R.C. Cattley, G. Elliott, K. Zhang, X. Feng, X.C. Jia, L. Green, R. Radinsky, and R. Kendall. 2006. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66(3):1721-1729.
30. Buttin, G. 1987. Exogenous Ig gene rearrangement in transgenic mice: A new strategy for human monoclonal antibody production? Trends Genet. 3:205-206.
31. Calvo, E., and E.K. Rowinsky. 2005. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr. Oncol. Rep. 7(2):96-103.
32. Chang, Q., Z. Zhong, A. Lees, M. Pekna, and L. Pirofski. 2002. Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect. Immun. 70:4977-4986.
33. Choi, T.K., P.W. Hollenbach, B.E. Pearson, R.M. Ueda, G.N. Weddell, C.G. Kurahara, C.S. Woodhouse, R.M. Kay, and J.F. Loring. 1993. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in ayeast artificial chromosome. Nature Genet. 4(2):117-123.
34. Cohen, B.D., D.A. Baker, C. Soderstrom, G. Tkalcevic, A.M. Rossi, P.E. Miller, M.W. Tengowski, F. Wang, A. Gualberto, J.S. Beebe, and J.D. Moyer. 2005. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. CancerRes. 11(5):2063-2073.
35. Cohen, S.B.; P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, M.C. Genovese, E.C. Keystone, J.E. Loveless, G.R. Burmester, M.W. Cravets, E.W. Hessey, T. Shaw, and M.C. Totoritis. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9):2793-2806.
36. Cohenuram, M., and M.W. Saif. 2007. Panitumumab the first fully human monoclonal antibody: From the bench to the clini. Anticancer Drugs 18(1):7-15.
37. Coiffier, B., C. Haioun, N. Ketterer, A. Engert, H. Tilly, D. Ma, P. Johnson, A. Lister, M. Feuring-Buske, J.A. Radford, R. Capdeville, V. Diehl, and F. Reyes. 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92(6):1927-1932.
38. Coiffier, B., S. Lepretre, L.M. Pedersen, O. Gadeberg, H. Fredriksen, M.H. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, M. Flensburg, J. Petersen, and T. Robak. 2008. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A phase I-II study. Blood 111(3):1094-1100.
39. Cook, G.P., and I.M. Tomlinson. 1995. The human immunoglobulin VH repertoire. Immunol. Today 16(5):237-242.
40. Costantini, F., and E. Lacy. 1981. Introduction of a rabbit beta-globin gene into the mouse germ line. Nature 294(5836):92-94.
41. Coughlin, M., G. Lou, O. Martinez, S.K. Masterman, O.A. Olsen, A.A. Moksa, M. Farzan, J.S. Babcook, and B.S. Prabhakar. 2006. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse((R)). Virology 361(1):93-102.
42. Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, and E. Van Cutsem. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in iri-notecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4):337-345.
43. Davis, M.M. 2004. The evolutionary and structural "logic" of antigen receptor diversity. Semin. Immunol. 16(4):239-243.
44. Davies, N.P., I.R. Rosewell, J.C. Richardson, G.P. Cook, M.S. Neuberger, B.H. Brownstein, M.L. Norris, and M. Bruggemann. 1993. Creation of mice expressing human antibody light chains by introduction of a yeast artificial chromosome containing the core region of the human immunoglobulin kappa locus. Biotechnology (NY) 11(8):911-914.
45. Dolloff, N.G., M.R. Russell, N. Loizos, and A. Fatatis. 2007. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res. 67(2):555-562.
46. Donohoe, M.E., G.B. Beck-Engeser, N. Lonberg, H. Karasuyama, R.L. Riley, H.M. Jack, and B.B. Blomberg. 2000. Transgenic human lambda 5 rescues the murine lambda 5 nullizygous phenotype. J. Immunol. 164(10):5269-5276.
47. Dornhofer, N., S. Spong, K. Bennewith, A. Salim, S. Klaus, N. Kambham, C. Wong, F. Kaper, P. Sutphin, R. Nacamuli, M. Hockel, Q. Le, M. Longaker, G. Yang, A. Koong, and A. Giaccia. 2006. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 66(11):5816-5827.
48. Downey, S.G., J.A. Klapper, F.O. Smith, J.C. Yang, R.M. Sherry, R.E. Royal, U.S. Kammula, M.S. Hughes, T.E. Allen, C.L. Levy, M. Yellin, G. Nichol, D.E. White, S.M. Steinberg, and S.A. Rosenberg. 2007. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22):6681-6688.
49. Ehrenstein, M.R., H.T. Cook, and M.S. Neuberger. 2000. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J. Exp. Med. 191(7):1253-1258.
50. Farr, C.D., M.R. Tabet, W.J. Ball, D.M. Fishwild, X. Wang, A.C. Nair, and W.J. Welsh. 2002. Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J. Med. Chem. 45(15):3257-3270.
51. Fishwild, D.M., D.V. Hudson, U. Deshpande, and A.H. Kung. 1999. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin. Immunol. 92(2):138-152.
52. Fishwild, D.M., S.L. O'Donnell, T. Bengoechea, D.V. Hudson, F. Harding, S.L. Bernhard, D. Jones, R.M. Kay, K.M. Higgins, S.R. Schramm, and N. Lonberg. 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nature Biotechnol. 14(7):845-851.
53. Foon, K.A., X.D. Yang, L.M. Weiner, A.S. Belldegrun, R.A. Figlin, J. Crawford, E.K. Rowinsky, J.P. Dutcher, N.J. Vogelzang, J. Gollub, J.A. Thompson, G. Schwartz, R.M. Bukowski, L.K. Roskos, and G.M. Schwab. 2004. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58(3):984-990.
54. Foote, J., and H.N. Eisen. 1995. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92(5):1254-1256.
55. Fraenkel, S., R. Mostoslavsky, T.I. Novobrantseva, R. Pelanda, J. Chaudhuri, G. Esposito, S. Jung, F.W. Alt, K. Rajewsky, H. Cedar, and Y. Bergman. 2007. Allelic "choice" governs somatic hypermutation in vivo at the immunoglobulin kappa-chain locus. Nature Immunol. 8(7):715-722.
56. Fuss, I.J., C. Becker, Z. Yang, C. Groden, R.L. Hornung, F. Heller, M.F. Neurath, W. Strober, and P.J. Mannon. 2006. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12(1):9-15.
57. Garambois, V., F. Glaussel, E. Foulquier, M. Ychou, M. Pugniere, R.X. Luo, B. Bezabeh, and A. Pelegrin. 2004. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer 4:75.
58. Gibson, T.B., A. Ranganathan, and A. Grothey. 2006. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer 6(1):29-31.
59. Glennie, M. J., R.R. French, M.S. Cragg, and R.P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44(16):3823-3837.
60. Goldstein, G. et al. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N. Engl. J. Med. 313(6):337-342.
61. Goodhardt, M., P. Cavelier, M.A. Akimenko, G. Lutfalla, C. Babinet, and F. Rougeon. 1987. Rearrangement and expression of rabbit immunoglobulin kappa light chain gene in transgenic mice. Proc. Natl. Acad. Sci. USA 84(12):4229-4233.
62. Gordon, J.W., and F.H. Ruddle. 1981. Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 214(4526):1244-1246.
63. Green, L.L., M.C. Hardy, C.E. Maynard-Currie, H. Tsuda, D.M. Louie,M.J. Mendez, H. Abderrahim, M. Noguchi, D.H. Smith, Y. Zeng, et al. 1994. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nature Genet. 7(1):13-21.
64. Green, L.L. and A. Jakobovits. 1998. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J. Exp. Med. 188(3):483-495.
65. Greenough, T.C., G.J. Babcock, A. Roberts, H.J. Hernandez, W.D. Thomas, J.A. Coccia, Jr, R.F. Graziano, M. Srinivasan, I. Lowy, R.W. Finberg, K. Subbarao, L. Vogel, M. Somasundaran, K. Luzuriaga, J.L. Sullivan, and D.M. Ambrosino. 2005. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immuno-prophylaxis in mice. J. Infect. Dis. 191(4):507-514.
66. Guloglu, F.B., and C.A. Roman. 2006. Precursor B cell receptor signaling activity can be uncoupled from surface expression. J. Immunol. 176(11):6862-6872.
67. Harbers, K., D. Jahner, and R. Jaenisch. 1981. Microinjection of cloned retroviral genomes into mouse zygotes: Integration and expression in the animal. Nature 293(5833):540-542.
68. Harding, F.A., and N. Lonberg. 1995. Class switching in human immunoglobulin transgenic mice. Ann. NY Acad. Sci. 764:536-546.
69. He, Y., W.J. Honnen, C.P. Krachmarov, M. Burkhart, S.C. Kayman, J. Corvalan, and A. Pinter. 2002. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J. Immunol. 169(1):595-605.
70. Heuck, F., J. Ellermann, P. Borchmann, A. Rothe, H. Hansen, A. Engert, and E.P. von Strandmann. 2004. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J. Immunother. (1997) 27(5):347-353.
71. Hodi, F.S., M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, M.V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, R. Padera, M.T. Jaklitsch, S. Shankar, T.C. Chen, A. Korman, J.P. Allison, and G. Dranoff. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100(8):4712-4717.
72. Holmes, E.H. 2001. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin. Investig. Drugs 10(3):511-519.
73. Horikawa, K., S.W. Martin, S.L. Pogue, K. Silver, K. Peng, K. Takatsu, and C.C. Goodnow. 2007. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J. Exp. Med. 204(4):759-769.
74. Huang, S., L. Mills, B. Mian, C. Tellez, M. McCarty, X.D. Yang, J.M. Gudas, and M. Bar-Eli. 2002. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161(1):125-134.
75. Huhn, D., C. von Schilling, M. Wilhelm, A.D. Ho, M. Hallek, R. Kuse, W. Knauf, U. Riedel, A. Hinke, S. Srock, S. Serke, C. Peschel, and B. Emmerich. 2001. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331.
76. Ignatovich, O., I.M. Tomlinson, P.T. Jones, and G. Winter. 1997. The creation of diversity in the human immunoglobulin V(lambda) repertoire. J. Mol. Biol. 268(1):69-77.
77. Imakiire, T., M. Kuroki, H. Shibaguchi, H. Abe, Y. Yamauchi, A. Ueno, Y. Hirose, H. Yamada, Y. Yamashita, T. Shirakusa, and I. Ishida. 2004. Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int. J. Cancer 108(8):564-570.
78. Inlay, M., F.W. Alt, D. Baltimore, and Y. Xu. 2002. Essential roles of the kappa light chain intronic enhancer and 3' enhancer in kappa rearrangement and demethylation. Nature Immunol. 3(5):463-468.
79. Ishida, I., K. Tomizuka, H. Yoshida, T. Tahara, N. Takahashi, A. Ohguma, S. Tanaka, M. Umehashi, H. Maeda, C. Nozaki, E. Halk, and N. Lonberg. 2002. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 4(1):91-102.
80. Itala, M., C.H. Geisler, E. Kimby, E. Juvonen, G. Tjonnfjord, K. Karlsson, and K. Remes. 2002. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a Nordic multicentre study. Eur. J. Haematol. 69(3):129-134.
81. Jaber, S.H., E.W. Cowen, L.R. Haworth, S.L. Booher, D.M. Berman, S.A. Rosenberg, and S.T. Hwang. 2006. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 142(2):166-172.
82. Jakobovits, A., R.G. Amado, X. Yang, L. Roskos, and G. Schwab. 2007. From XenoMouse technology to panitu-mumab, the first fully human antibody product from transgenic mice. Nature Biotechnol. 25(10):1134-1143.
83. Jakobovits, A., A.L. Moore, L.L. Green, G.J. Vergara, C.E. Maynard-Currie, H.A. Austin, and S. Klapholz. 1993. Germ-line transmission and expression of a human-derived yeast artificial chromosome. Nature 362(6417):255-258.
84. Jones, P.T., P.H. Dear, J. Foote, M.S. Neuberger, and G. Winter. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069):522-525.
85. Kanmaz, T., J.J. Fechner, J. Torrealba, Jr, H.T. Kim, Y. Dong, T.D. Oberley, J.M. Schultz, D.D. Bloom, M. Katayama, W. Dar, J. Markovits, W. Schuler, H. Hu, M.M. Hamawy, and S.J. Knechtle. 2004. Monotherapy with the novel human anti-CD154 monoclonal antibody AB1793 in rhesus monkey renal transplantation model. Transplantation 77(6):914-920.
86. Kasper, L.H., D. Everitt, T.P. Leist, K.A. Ryan, M.A. Mascelli, K. Johnson, A. Raychaudhuri, and T. Vollmer. 2006. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr. Med. Res. Opin. 22(9):1671-1678.
87. Kauffman, C.L., N. Aria, E. Toichi, T.S. McCormick, K.D. Cooper, A.B. Gottlieb, D.E. Everitt, B. Frederick, Y. Zhu, M.A. Graham, C.E. Pendley, and M.A. Mascelli. 2004. A phase I study evaluating the safety, pharma-cokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123(6):1037-1044.
88. Keler, T., E. Halk, L. Vitale, T. O'Neill, D. Blanset, S. Lee, M. Srinivasan, R.F. Graziano, T. Davis, N. Lonberg, and A. Korman. 2003. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 171(11):6251-6259.
89. Kim, Y.H., M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, S. Whittaker, T.M. Illidge, T. Schwarz, R. Kaufmann, K. Cooper, K.M. Knudsen, S. Lisby, O. Baadsgaard, and S.J. Knox. 2007. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109(11): 4655-4662.
90. Klimm, B., R. Schnell, V. Diehl, and A. Engert. 2005. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 90(12):1680-1692.
91. Korman, A.J., K. S. Peggs, and J.P. Allison. 2006. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90:297-339.
92. Kraus, M., M.B. Alimzhanov, N. Rajewsky, and K. Rajewsky. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117(6):787-800.
93. Krueger, G.G., R.G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, L.T. Dooley, and M. Lebwohl. 2007. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356(6):580-592.
94. Kumazaki, K., B. Tirosh, R. Maehr, M. Boes, T. Honjo, and H.L. Ploegh. 2007. AID-/-mus-/-mice are agammaglobulinemic and fail to maintain B220-CD138+ plasma cells. J. Immunol. 178(4):2192-2203.
95. Kuroiwa, Y., K. Tomizuka, T. Shinohara, Y. Kazuki, H. Yoshida, A. Ohguma, T. Yamamoto, S. Tanaka, M. Oshimura, and I. Ishida. 2000. Manipulation of human minichromosomes to carry greater than mega-base-sized chromosome inserts. Nature Biotechnol. 18(10):1086-1090.
96. Kuroki, M., H. Yamada, H. Shibaguchi, K. Hachimine, Y. Hirose, T. Kinugasa, and I. Ishida. 2005. Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions. Anticancer Res. 25(6A):3733-3739.
97. Kuus-Reichel, K., L.S. Grauer, L.M. Karavodin, C. Knott, M. Krusemeier, and N.E. Kay. 1994. Will immunogeni-city limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1(4):365-372.
98. Lammerts van Bueren J.J., W.K. Bleeker, H.O. Bogh, M. Houtkamp, J. Schuurman, J.G. van de Winkel, and P.W. Parren. 2006. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action. Cancer Res. 66(15):7630-7638.
99. Leach, D.R., M.F. Krummel, and J.P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-1736.
100. Lenz, H.J., E. Van Cutsem, S. Khambata-Ford, R.J. Mayer, P. Gold, P. Stella, B. Mirtsching, A.L. Cohn, A.W. Pippas, N. Azarnia, Z. Tsuchihashi, D.J. Mauro, and E.K. Rowinsky. 2006. Multicenter phase II and trans-lational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoro-pyrimidines. J. Clin. Oncol. 24(30):4914-4921.
101. Lewiecki, E.M., P.D. Miller, M.R. McClung, S.B. Cohen, M.A. Bolognese, Y. Liu, A. Wang, S. Siddhanti, and L.A. Fitzpatrick. 2007. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of post-menopausal women with low bone mineral density. J. Bone Miner. Res. 22(12):1832-1841.
102. Lipton, A., G.G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.J. Body, R. de Boer, R. Berardi, P. Gascon, K.S. Tonkin, R. Coleman, A.H. Paterson, M.C. Peterson, M. Fan, A. Kinsey, and S. Jun. 2007. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25(28):4431-4437.
103. Lonberg, N. 2005. Human antibodies from transgenic animals. Nature Biotechnol. 23(9):1117-1125.
104. Lonberg, N., and D. Huszar. 1995. Human antibodies from transgenic mice. Int. Rev. Immunol. 13(1):65-93.
105. Lonberg, N., L.D. Taylor, F.A. Harding, M. Trounstine, K.M. Higgins, S.R. Schramm, C.C. Kuo, R. Mashayekh, K. Wymore, J.G. McCabe, et al. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368(6474):856-859.
106. Ma, D., C.E. Hopf, A.D. Malewicz, G.P. Donovan, P.D. Senter, W.F. Goeckeler, P.J. Maddon, and W.C. Olson. 2006. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 12(8):2591-2596.
107. Maini, R.N., F.C. Breedveld, J.R. Kalden, J.S. Smolen, D. Davis, J.D. Macfarlane, C. Antoni, B. Leeb, M.J. Elliott, J.N. Woody, T.F. Schaible, and M. Feldmann. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9):1552-1563.
108. Maitta, R.W., K. Datta, Q. Chang, R.X. Luo, B. Witover, K. Subramaniam, and L.A. Pirofski. 2004. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylo-mannan manifest different specificities and gene use profiles. Infect Immun. 72(8):4810-4818.
109. Maker, A.V., P. Attia, and S.A. Rosenberg. 2005. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175(11):7746-7754.
110. Maker, A.V., G.Q. Phan, P. Attia, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, L.R. Haworth, C. Levy, D. Kleiner, S.A. Mavroukakis, M. Yellin, and S.A. Rosenberg. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann. Surg. Oncol. 12(12):1005-1016.
111. Maker, A.V., J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, M. Hughes, M.J. Yellin, L.R. Haworth, C. Levy, T. Allen, S.A. Mavroukakis, P. Attia, and S.A. Rosenberg. 2006. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. (1997) 29(4):455-463.
112. Mannon, P.J., I.J. Fuss, L. Mayer, C.O. Elson, W.J. Sandborn, D. Present, B. Dolin, N. Goodman, C. Groden, R.L. Hornung, M. Quezado, Z. Yang, M.F. Neurath, J. Salfeld, G.M. Veldman, U. Schwertschlag, and W. Strober. 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351(20):2069-2079.
113. Mansour, S.L., K.R. Thomas, and M.R. Capecchi. 1988. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 336(6197):348-352.
114. Martin, P.L., Q. Jiao, J. Cornacoff, W. Hall, B. Saville, J.A. Nemeth, A. Schantz, M. Mata, H. Jang, A.A. Fasanmade, L. Anderson, M.A. Graham, H.M. Davis, and G. Treacy. 2005. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin. Cancer Res. 11(19):6959-6965.
115. Martin, P.L., S. Oneda, and G. Treacy. 2007. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am. J. Reprod. Immunol. 58(2):138-149.
116. McCafferty, J., A.D. Griffiths, G. Winter, and D.J. Chiswell. 1990. Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 348(6301):552-554.
117. McClung, M.R., E.M. Lewiecki, S.B. Cohen, M.A. Bolognese, G.C. Woodson, A.H. Moffett, M. Peacock, P.D. Miller, S.N. Lederman, C.H. Chesnut, D. Lain, A.J. Kivitz, D.L. Holloway, C. Zhang, M.C. Peterson, and P.J. Bekker. 2006. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354(8):821-831.
118. Meffre, E., M. Milili, C. Blanco-Betancourt, H. Antunes, M.C. Nussenzweig, and C. Schiff. 2001. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J. Clin. Invest. 108(6):879-886.
119. Melchers, F. 2005. The pre-B-cell receptor: Selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nature Rev. Immunol. 5(7):578-584.
120. Mendez, M.J., L.L. Green, J.R. Corvalan, X.C. Jia, C.E. Maynard-Currie, X.D. Yang, M.L. Gallo, D.M. Louie, D.V. Lee, K.L. Erickson, J. Luna, C.M. Roy, H. Abderrahim, F. Kirschenbaum, M. Noguchi, D.H. Smith, A. Fukushima, J.F. Hales, S. Klapholz, M.H. Finer, C.G. Davis, K.M. Zsebo, and A. Jakobovits. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genet. 15(2):146-156.
121. Melnikova, V.O., and M. Bar-Eli. 2006. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 19(5):395-405.
122. Milili, M., C. Schiff, M. Fougereau, and C. Tonnelle. 1996. The VDJ repertoire expressed in human preB cells reflects the selection of bona fide heavy chains. Eur. J. Immunol. 26(1):63-69.
123. Morrison, S.L., M.J. Johnson, L.A. Herzenberg, and V.T. Oi. 1984. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81(21):6851-6855.
124. Mori, E., M. Thomas, K. Motoki, K. Nakazawa, T. Tahara, K. Tomizuka, I. Ishida, and S. Kataoka. 2004. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ. 11(2):203-207.
125. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S.M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002a. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70(2):612-619.
126. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S.M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002b. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70(10):5896-5899.
127. Muramatsu, M., K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102(5):553-563.
128. Nagy, A.G.M., K. Vinterstein, et al. 2003. Manipulating the mouse embryo: A laboratory manual, 3rd edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
129. Nicholson, I.C., X. Zou, A.V. Popov, G.P. Cook, E.M. Corps, S. Humphries, C. Ayling, B. Goyenechea, J. Xian, M.J. Taussig, M.S. Neuberger, and M. Bruggemann. 1999. Antibody repertoires of four-and five-feature trans-locus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J. Immunol. 163(12):6898-6906.
130. Nozawa, S., D. Aoki, K. Tsukazaki, N. Susumu, M. Sakayori, N. Suzuki, A. Suzuki, R. Wakita, M. Mukai, Y. Egami, K. Kojima-Aikawa, I. Ishida, F. Belot, O. Hindsgaul, M. Fukuda, and M.N. Fukuda. 2004. HMMC-1: A humanized monoclonal antibody with therapeutic potential against Mullerian duct-related carcinomas. Clin. Cancer Res. 10(20):7071-7078.
131. O'Brien, S.M., H. Kantarjian, D.A. Thomas, F.J. Giles, E.J. Freireich, J. Cortes, S. Lerner, and M.J. Keating. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19(8):2165-2170.
132. O'Mahony, D., J.C. Morris, C. Quinn, W. Gao, W.H. Wilson, B. Gause, S. Pittaluga, S. Neelapu, M. Brown, T.A. Fleisher, J.L. Gulley, J. Schlom, R. Nussenblatt, P. Albert, T.A. Davis, I. Lowy, M. Petrus, T.A. Waldmann, and J.E. Janik. 2007. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. CancerRes. 13(3):958-964.
133. Ostendorf, T., C.R.C. van Roeyen, J.D. Peterson, U. Kunter, R. Eitner, A.J. Hamad, G. Chan, X.C. Jia, J. Macaluso, G. Gazit-Bornstein, B.A. Keyt, H.S. Lichenstein, W.J. LaRochelle, and J. Floege. 2003. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 14(9):2237-2247.
134. Parren, P.W., P.A. Warmerdam, L.C. Boeije, J. Arts, N.A. Westerdaal, A. Vlug, P.J. Capel, L.A. Aarden, and J.G. van de Winkel. 1992. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90(4):1537-1546.
135. Parry, R., D. Schneider, D. Hudson, D. Parkes, J.A. Xuan, A. Newton, P. Toy, R. Lin, R. Harkins, B. Alicke, S. Biroc, P.J. Kretschmer, M. Halks-Miller, H. Klocker, Y. Zhu, B. Larsen, R.R. Cobb, P. Bringmann, G. Roth, J.S. Lewis, H. Dinter, and G. Parry. 2005. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 65(18):8397-8405.
136. Pendley, C., A. Schantz, and C. Wagner. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5(2):172-179.
137. Phan, G.Q., J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, N.P. Restifo, L.R. Haworth, C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, P.H. Duray, S.M. Steinberg, J.P. Allison, T.A. Davis, and S.A. Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100(14):8372-8377.
138. Popov, A.V., X. Zou, J. Xian, I.C. Nicholson, and M. Bruggemann. 1999. A human immunoglobulin lambda locus is similarly well expressed in mice and humans. J. Exp. Med. 189(10):1611-1620.
139. Ramakrishna, V., J.F. Treml, L. Vitale, J.E. Connolly, T. O'Neill, P.A. Smith, C.L. Jones, L.Z. He, J. Goldstein, P.K. Wallace, T. Keler, and M.J. Endres. 2004. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J. Immunol. 172(5):2845-2852.
140. Rathanaswami, P., S. Roalstad, L. Roskos, Q.J. Su, S. Lackie, and J. Babcook. 2005. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem. Biophys. Res. Commun. 334(4):1004-1013.
141. Razai, A., C. Garcia-Rodriguez, J. Lou, I.N. Geren, C.M. Forsyth, Y. Robles, R. Tsai, T.J. Smith, L.A. Smith, R.W. Siegel, M. Feldhaus, and J.D. Marks. 2005. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J. Mol. Biol. 351(1):158-169.
142. Reuben, J.M., B.N. Lee, C. Li, J. Gomez-Navarro, V.A. Bozon, C.A. Parker, I.M. Hernandez, C. Gutierrez, G. Lopez-Berestein, and L.H. Camacho. 2006. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106(11):2437-2444.
143. Reynaud, S., L. Delpy, L. Fleury, H.L. Dougier, C. Sirac, and M. Cogne. 2005. Interallelic class switch recombination contributes significantly to class switching in mouse B cells. J. Immunol. 174(10):6176-6183.
144. Ribas, A., L.H. Camacho, G. Lopez-Berestein, D. Pavlov, C.A. Bulanhagui, R. Millham, B. Comin-Anduix, J.M. Reuben, E. Seja, C.A. Parker, A. Sharma, J.A. Glaspy, and J. Gomez-Navarro. 2005. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23(35):8968-8977.
145. Ribas, A., J.A. Glaspy, Y. Lee, V.B. Dissette, E. Seja, H.T. Vu, N.S. Tchekmedyian, D. Oseguera, B. Comin-Anduix, J.A. Wargo, S.N. Amarnani, W.H. McBride, J.S. Economou, and L.H. Butterfield. 2004. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. (1997) 27(5):354-367.
146. Ribas, A., D.C. Hanson, D.A. Noe, R. Millham, D.J. Guyot, S.H. Bernstein, P.C. Canniff, A. Sharma, and J. Gomez-Navarro. 2007. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12(7):873-883.
147. Rider, D.A., C.E. Havenith, R. de Ridder, J. Schuurman, C. Favre, J.C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J.G. van de Winkel, J. Cambier, P.W. Parren, D.R. Alexander. 2007. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 67(20):9945-9953.
148. Roost, H.P., M.F. Bachmann, A. Haag, U. Kalinke, V. Pliska, H. Hengartner, and R.M. Zinkernagel. 1995. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc. Natl. Acad. Sci. USA 92(5):1257-1261.
149. Rosner, K., D.B. Winter, R.E. Tarone, G.L. Skovgaard, V.A. Bohr, and P.J. Gearhart. 2001. Third complementarity-determining region of mutated VH immunoglobulin genes contains shorter V, D, J, P, and N components than non-mutated genes. Immunology 103(2):179-187.
150. Rowinsky, E.K., G.H. Schwartz, J.A. Gollob, J.A. Thompson, N.J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y.P. Li, R. Arends, K.A. Foon, G. Schwab, and J. Dutcher. 2004. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22(15):3003-3015.
151. Sanderson, K., R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, M. Yellin, and J. Weber. 2005. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23(4):741-750.
152. Schedl, A., Z. Larin, L. Montoliu, E. Thies, G. Kelsey, H. Lehrach, and G. Schutz. 1993. A method for the generation of YAC transgenic mice by pronuclear microinjection. Nucleic Acids Res. 21(20):4783-4787.
153. Schelonka, R.L., I.I. Ivanov, D.H. Jung, G.C. Ippolito, L. Nitschke, Y. Zhuang, G.L. Gartland, J. Pelkonen, F.W. Alt, K. Rajewsky, and H.W. Schroeder, Jr. 2005. A single DH gene segment creates its own unique CDR-H3 repertoire and is sufficient for B cell development and immune function. J. Immunol. 175(10):6624-6632.
154. Schuler, W., M. Bigaud, V. Brinkmann, F. Di Padova, S. Geisse, H. Gram, V. Hungerford, B. Kleuser, C. Kristofic, K. Menninger, R. Tees, G. Wieczorek, C. Wilt, C. Wioland, and M. Zurini. 2004. Efficacyand safety of AB1793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 77(5):717-726.
155. Schwartzberg, P.L., S.P. Goff, and E.J. Robertson. 1989. Germ-line transmission of a c-abl mutation produced by targeted gene disruption in ES cells. Science 246(4931):799-803.
156. Schwarz, E.M. and C.T. Ritchlin. 2007. Clinical development of anti-RANKL therapy. Arthritis Res. Ther. 9 (Suppl 1):S7.
157. Seshasayee, D., W.P. Lee, M. Zhou, J. Shu, E. Suto, J. Zhang, L. Diehl, C.D. Austin, Y.G. Meng, M. Tan, S.L. Bullens, S. Seeber, M.E. Fuentes, A.F. Labrijn, Y.M. Graus, L.A. Miller, E.S. Schelegle, D.M. Hyde, L.C. Wu, S.G. Hymowitz, and F. Martin. 2007. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 117(12):3868-3878.
158. Sheoran, A.S., S. Chapman-Bonofiglio, B.R. Harvey, J. Mukherjee, G. Georgiou, A. Donohue-Rolfe, and S. Tzipori. 2005. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect. Immun. 73(8):4607-4613.
159. Shimizu, T., C. Mundt, S. Licence, F. Melchers, and I.L. Martensson. 2002. VpreB1/VpreB2/lambda 5 triple-deficient mice show impaired B cell development but functional allelic exclusion of the IgH locus. J. Immunol. 168(12):6286-6293.
160. Skov, L., K. Kragballe, C. Zachariae, E.R. Obitz, E.A. Holm, G.B. Jemec, H. Solvsten, H.H. Ibsen, L. Knudsen, P. Jensen, J.H. Petersen, T. Menne, and O. Baadsgaard. 2003. HuMax-CD4: A fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. 139(11):1433-1439.
161. Sloan, S.E., C. Hanlon, W. Weldon, M. Niezgoda, J. Blanton, J. Self, K.J. Rowley, R.B. Mandell, G.J. Babcock, W.D. Thomas, C.D. Rupprecht, Jr, and D.M. Ambrosino. 2007. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25(15):2800-2810.
162. Small, E.J., N.S. Tchekmedyian, B.I. Rini, L. Fong, I. Lowy, and J.P. Allison. 2007. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13(6):1810-1815.
163. Strauss, W.M., J. Dausman, C. Beard, C. Johnson, J.B. Lawrence, and R. Jaenisch. 1993. Germ line transmission of a yeast artificial chromosome spanning the murine alpha 1(I) collagen locus. Science 259(5103):1904-1907.
164. Suarez, E., R. Yaňez, Y. Barrios, and R. Diaz-Espada. 2004. Human monoclonal antibodies produced in transgenic BABkappa, lambda mice recognising idiotypic immunoglobulins of human lymphoma cells. Mol. Immunol. 41(5):519-526.
165. Suzuki, N., D. Aoki, Y. Tamada, N. Susumu, K. Orikawa, K. Tsukazaki, M. Sakayori, A. Suzuki, T. Fukuchi, M. Mukai, K. Kojima-Aikawa, I. Ishida, and S. Nozawa. 2004. HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. Gynecol. Oncol. 95(2):290-298.
166. Tai, Y.T., X. Li, X. Tong, D. Santos, T. Otsuki, L. Catley, O. Tournilhac, K. Podar, T. Hideshima, R. Schlossman, P. Richardson, N.C. Munshi, M. Luqman, and K.C. Anderson. 2005. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 65(13):5898-5906.
167. Tarhini, A.A., and J.M. Kirkwood. 2007. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr. Opin. Mol. Ther. 9(5):505-514.
168. Taylor, L.D., C.E. Carmack, D. Huszar, K.M. Higgins, R. Mashayekh, G. Sequar, S.R. Schramm, C.C. Kuo, S.L. O'Donnell, R.M. Kay, et al. 1994. Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int. Immunol. 6(4):579-591.
169. Taylor, L.D., C.E. Carmack, S.R. Schramm, R. Mashayekh, K.M. Higgins, C.C. Kuo, C. Woodhouse, R.M. Kay, and N. Lonberg. 1992. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 20(23):6287-6295.
170. Teeling, J.L., R.R. French, M.S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P.W. Parren, C.E. Hack, M. Dechant, T. Valerius, J.G. van de Winkel, and M.J. Glennie. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6):1793-1800.
171. Teeling, J.L., W.J. Mackus, L.J. Wiegman, J.H. van den Brakel, S.A. Beers, R.R. French, T. van Meerten, S. Ebeling, T. Vink, J.W. Slootstra, P.W. Parren, M.J. Glennie, and J.G. van de Winkel. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177(1):362-371.
172. Thompson, R.H., J.P. Allison, and E.D. Kwon. 2006. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immu-notherapy for the treatment of prostate cancer. Urol. Oncol. 24(5):442-447.
173. Toichi, E., G. Torres, T.S. McCormick, T. Chang, M.A. Mascelli, C.L. Kauffman, N. Aria, A.B. Gottlieb, D.E. Everitt, B. Frederick, C.E. Pendley, and K.D. Cooper. 2006. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177(7):4917-4926.
174. Tomizuka, K., T. Shinohara, H. Yoshida, H. Uejima, A. Ohguma, S. Tanaka, K. Sato, M. Oshimura, and I. Ishida. 2000. Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc. Natl. Acad. Sci. USA 97(2):722-727.
175. Tomizuka, K., H. Yoshida, H. Uejima, H. Kugoh, K. Sato, A. Ohguma, M. Hayasaka, K. Hanaoka, M. Oshimura, and I. Ishida. 1997. Functional expression and germline transmission of a human chromosome fragment in chi-maeric mice. Nature Genet. 16(2):133-143.
176. Tomlinson, I.M., J.P. Cox, E. Gherardi, A.M. Lesk, and C. Chothia. 1995. The structural repertoire of the human V kappa domain. EMBO J. 14(18):4628-4638.
177. Tomlinson, I.M., G. Walter, P.T. Jones, P.H. Dear, E.L. Sonnhammer, and G. Winter. 1996. The imprint of somatic hypermutation on the repertoire of human germline V genes. J. Mol. Biol. 256(5):813-817.
178. Trikha, M., Z. Zhou, J.A. Nemeth, Q. Chen, C. Sharp, E. Emmell, J. Giles-Komar, and M.T. Nakada. 2004. CNTO 95, a fully human monoclonal antibody that inhibits alpha v integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110(3):326-335.
179. Tze, L.E., B.R. Schram, K.P. Lam, K.A. Hogquist, K.L. Hippen, J. Liu, S.A. Shinton, K.L. Otipoby, P.R. Rodine, A.L. Vegoe, M. Kraus, R.R. Hardy, M.S. Schlissel, K. Rajewsky, and T.W. Behrens. 2005. Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS Biol. 3(3):e82.
180. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17(4):926-941.
181. Van Cutsem, E., M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J.L. Canon, J.L. VanLaethem, J. Maurel, G. Richardson, M. Wolf, and R.G. Amado. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic color-ectal cancer. J. Clin. Oncol. 25(13):1658-1664.
182. van de Putte, L.B., C. Atkins, M. Malaise, J. Sany, A.S. Russell, P.L. van Riel, L. Settas, J.W. Bijlsma, S. Todesco, M. Dougados, P. Nash, P. Emery, N. Walter, M. Kaul, S. Fischkoff, and H. Kupper. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying anti-rheumatic drug treatment has failed. Ann. Rheum. Dis. 63(5):508-516.
183. van Royen-Kerkhof, A., E.A. Sanders, V. WaLraven, M. Voorhorst-Ogink, E. Saeland, J.L. Teeling, A. Gerritsen, M.A. van Dijk, W. Kuis, G.T. Rijkers, L. Vitale, T. Keler, S.E. McKenzie, J.H. Leusen, and J.G. van de Winkel. 2005. A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice. Br. J. Haematol. 130(1):130-137.
184. Villadsen, L.S., J. Schuurman, F. Beurskens, T.N. Dam, F. Dagnaes-Hansen, L. Skov, J. Rygaard, M.M. Voorhorst-Ogink, A.F. Gerritsen, M.A. van Dijk, P.W. Parren, O. Baadsgaard, and J.G. van de Winkel. 2003. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112(10):1571-1580.
185. Villadsen, L.S., L. Skov, T.N. Dam, F. Dagnaes-Hansen, J. Rygaard, J. Schuurman, P.W. Parren, J.G. van de Winkel, and O. Baadsgaard. 2007. In situ depletion of CD4+ T cells in human skin by Zanolimumab. Arch. Dermatol. Res. 298(9):449-455.
186. Vitale, L., D. Blanset, I. Lowy, T. O'Neill, J. Goldstein, S.F. Little, G.P. Andrews, G. Dorough, R.K. Taylor, and T. Keler. 2006. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect. Immun. 74(10):5840-5847.
187. Vonderheide, R.H. 2007. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13(4):1083-1088.
188. Vonderheide, R.H., K.T. Flaherty, M. Khalil, M.S. Stumacher, D.L. Bajor, N.A. Hutnick, P. Sullivan, J.J. Mahany, M. Gallagher, A. Kramer, S.J. Green, P.J. O'Dwyer, K.L. Running, R.D. Huhn, and S.J. Antonia. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25(7):876-883.
189. Wagner, E.F., T.A. Stewart, and B. Mintz. 1981. The human beta-globin gene and a functional viral thymidine kinase gene in developing mice. Proc. Natl. Acad. Sci. USA 78(8):5016-5020.
190. Wagner, T.E., P.C. Hoppe, J.D. Jollick, D.R. Scholl, R.L. Hodinka, and J.B. Gault. 1981. Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression in adult mice and their offspring. Proc. Natl. Acad. Sci. USA 78(10):6376-6380.
191. Wang, Y., J. Hailey, D. Williams, P. Lipari, M. Malkowski, X. Wang, L. Xie, G. Li, D. Saha, W.L. Ling, S. Cannon-Carlson, R. Greenberg, R.A. Ramos, R. Shields, L. Presta, P. Brams, W.R. Bishop, and J.A. Pachter. 2005. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 4(8):1214-1221.
192. Weber, J. 2007. Review: Anti-CTLA-4 antibody ipilimumab-case studies of clinical response and immune-related adverse events. Oncologist 12(7):864-872.
193. Weinblatt, M.E., E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, C.A. Birbara, L.A. Teoh, S.A. Fischkoff, and E.K. Chartash. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 48(1):35-45.
194. Weng, W.K. and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21(21):3940-3947.
195. Williams, S.C., J.P. Frippiat, I.M. Tomlinson, O. Ignatovich, M.P. Lefranc, and G. Winter. 1996. Sequence and evolution of the human germline V lambda repertoire. J. Mol. Biol. 264(2):220-232.
196. Winkler, U., M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert. 1999. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94(7):2217-2224.
197. Wong, R.M., R.R. Scotland, R.L. Lau, C. Wang, A.J. Korman, W.M. Kast, and J.S. Weber. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 19(10):1223-1234.
198. Xu, J.L., and M.M. Davis. 2000. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13(1):37-45.
199. Yamamura, K., A. Kudo, T. Ebihara, K. Kamino, K. Araki, Y. Kumahara, and T. Watanabe. 1986. Cell-type-specific and regulated expression of a human gamma 1 heavy-chain immunoglobulin gene in transgenic mice. Proc. Natl. Acad. Sci. USA 83(7):2152-2156.
200. Yang, X.D., J.R. Corvalan, P. Wang, C.M. Roy, and C.G. Davis. 1999. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. 66(3):401-410.
201. Yang, X.D., X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis. 2001. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38(1):17-23.
202. Yang, X.D., X.C. Jia, J.R. Corvalan, P. Wang, C.G. Davis, and A. Jakobovits. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59(6):1236-1243.
203. Zang, X., and J.P. Allison. 2007. The b7 family and cancer therapy: Costimulation and coinhibition. Clin. Cancer Res. 13(18, Pt 1):5271-5279.
204. Zhou, H., H. Jang, R.M. Fleischmann, E. Bouman-Thio, Z. Xu, J.C. Marini, C. Pendley, Q. Jiao, G. Shankar, S.J. Marciniak, S.B. Cohen, M.U. Rahman, D. Baker, M.A. Mascelli, H.M. Davis, and D.E. Everitt. 2007. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47(3):383-396.
205. Zijlstra, M., E. Li, F. Sajjadi, S. Subramani, and R. Jaenisch. 1989. Germ-line transmission of a disrupted beta 2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature 342(6248):435-438.
206. Zou, Y.R., W. Muller, H. Gu, and K. Rajewsky. 1994. Cre-loxP-mediated gene replacement: A mouse strain producing humanized antibodies. Curr. Biol. 4(12):1099-1103.
207. Zou, X., T.A. Piper, J.A. Smith, N.D. Allen, J. Xian, and M. Bruggemann. 2003. Block in development at the pre-B-IIto immature B cell stage in mice without Ig kappa and Ig lambda light chain. J. Immunol. 170(3):1354-1361.